How do in-vitro release profiles of nanosuspensions from Alzet® pumps correspond to the in-vivo situation? A case study on radiolabeled fenofibrate

Journal of Controlled Release

Volumn 168, Issue 1, 2013, Pages 77-87

  Hill, A ^a,b   Breyer, S ^c   Geissler, S ^b   Mier, W ^c   Haberkorn, U ^c   Weigandt, M ^b   Mader K ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b Merck Serono GmbH   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Nanosuspensions; Organ distribution; Osmotic pumps; Radioimaging; Subcutaneous

Indexed keywords

NANO-SUSPENSIONS; ORGAN DISTRIBUTION; OSMOTIC PUMPS; RADIOIMAGING; SUBCUTANEOUS;

KINETICS; NUCLEAR MEDICINE; OSMOSIS;

PUMPS;

FENOFIBRATE; IODINE 131;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG RELEASE; GAMMA SCINTIGRAPHY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; KINETICS; MOUSE; NANOSUSPENSION; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL;

ANIMALS; DRUG DELIVERY SYSTEMS; FEMALE; FENOFIBRATE; INFUSION PUMPS, IMPLANTABLE; IODINE ISOTOPES; MICE; NANOSTRUCTURES; SUSPENSIONS; TISSUE DISTRIBUTION;

EID: 84875924178     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.03.005     Document Type: Article

References (53)

1. J.P. Möschwitzer Drug nanocrystals in the commercial pharmaceutical development process Int. J. Pharm. 2012 10.1016/j.ijpharm.2012.09.034
2. K. Kawakami Modification of physicochemical characteristics of active pharmaceutical ingredients and application of supersaturatable dosage forms for improving bioavailability of poorly absorbed drugs Adv. Drug Deliv. Rev. 64 2012 480 495
3. B.E. Rabinow Nanosuspensions in drug delivery Nat. Rev. Drug Discov. 3 2004 785 796
4. E. Merisko-Liversidge, G.G. Liversidge, and E.R. Cooper Nanosizing: a formulation approach for poorly-water-soluble compounds Eur. J. Pharm. Sci. 18 2003 113 120
5. B.V. Eerdenbrugh, G.V. den Mooter, and P. Augustijns Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products Int. J. Pharm. 364 2008 64 75
6. H.S.M. Ali, P. York, and N. Blagden Preparation of hydrocortisone nanosuspension through a bottom-up nanoprecipitation technique using microfluidic reactors Int. J. Pharm. 375 2009 107 113
7. J. Hu, K.P. Johnston, and R.O. Williams III Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs Drug Dev. Ind. Pharm. 30 2004 233 245
8. J. Wong, A. Brugger, A. Khare, M. Chaubal, P. Papadopoulos, B. Rabinow, J. Kipp, and J. Ning Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects Adv. Drug Deliv. Rev. 60 2008 939 954
9. S. Herrlich, S. Spieth, S. Messner, and R. Zengerle Osmotic micropumps for drug delivery Adv. Drug Deliv. Rev. 64 2012 1617 1627
10. S. Neervannan Preclinical formulations for discovery and toxicology: physicochemical challenges Expert Opin. Drug Metab. Toxicol. 2 2006 715 731
11. G. van 't Klooster, E. Hoeben, H. Borghys, A. Looszova, M.P. Bouche, F. van Velsen, and L. Baert Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation Antimicrob. Agents Chemother. 54 2010 2042 2050
12. L. Baert, G. van 't Klooster, W. Dries, M. Francois, A. Wouters, E. Basstanie, K. Iterbeke, F. Stappers, P. Stevens, L. Schueller, P.V. Remoortere, G. Kraus, P. Wigerinck, and J. Rosier Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment Eur. J. Pharm. Biopharm. 72 2009 502 508
13. P.C. Chiang, Y. Ran, K.J. Chou, Y. Cui, and H. Wong Investigation of utilization of nanosuspension formulation to enhance exposure of 1,3-dicyclohexylurea in rats: preparation for PK/PD study via subcutaneous route of nanosuspension drug delivery Nanoscale Res. Lett. 6 2011 1 9
14. S.L. De, P. Colin, W. Ceelen, M. Bracke, B.J. Van, J.P. Remon, and C. Vervaet Development of a nanocrystalline paclitaxel formulation for hipec treatment Pharm. Res. 29 2012 2398 2406
15. P. Sharma, Z.D. Zujovic, G.A. Bowmaker, W.A. Denny, and S. Garg Evaluation of a crystalline nanosuspension: polymorphism, process induced transformation and in vivo studies Int. J. Pharm. 408 2011 138 151
16. S. Ganta, J.W. Paxton, B.C. Baguley, and S. Garg Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery Int. J. Pharm. 367 2009 179 186
17. J.L. Wahlstrom, P.C. Chiang, S. Ghosh, C.J. Warren, S.P. Wene, L.A. Albin, M.E. Smith, and S.L. Roberds Pharmacokinetic evaluation of a 1,3-dicyclohexylurea nanosuspension formulation to support early efficacy assessment Nanoscale Res. Lett. 2 2007 291 296
18. B. Rabinow, J. Kipp, P. Papadopoulos, J. Wong, J. Glosson, J. Gass, C.S. Sun, T. Wielgos, R. White, C. Cook, K. Barker, and K. Wood Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat Int. J. Pharm. 339 2007 251 260
19. R. Shegokar, and K.K. Singh Nevirapine nanosuspensions for HIV reservoir targeting Pharmazie 66 2011 408 415
20. E.A. Simone, B.J. Zern, A.M. Chacko, J.L. Mikitsh, E.R. Blankemeyer, S. Muro, R.V. Stan, and V.R. Muzykantov Endothelial targeting of polymeric nanoparticles stably labeled with the PET imaging radioisotope iodine-124 Biomaterials 33 2012 5406 5413
21. D. Psimadas, P. Georgoulias, V. Valotassiou, and G. Loudos Molecular nanomedicine towards cancer: 111In-labeled nanoparticles J. Pharm. Sci. 101 2012 2271 2280
22. S. Breyer, A. Semmler, T. Miller, A. Hill, S. Geissler, U. Haberkorn, and W. Mier Radioiodinated dechloro-4-iodofenofibrate: a hydrophobic model drug for molecular imaging studies Int. J. Pharm. 431 2012 78 83
23. A. Hill, S. Geissler, M. Weigandt, and K. Mäder Controlled delivery of nanosuspensions from osmotic pumps: zero order and non-zero order kinetics J. Control. Release 158 2012 403 412
24. P.N. Hawkins, C. Aprile, G. Capri, L. Vigano, E. Munzone, L. Gianni, M.B. Pepys, and G. Merlini Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis Eur. J. Nucl. Med. 25 1998 701 708
25. F.O. Roberts, D.H. Gunawardana, K. Pathmaraj, A. Wallace, and U. PL, T. Mi, S.U. Berlangieri, G.J. O'Keefe, C.C. Rowe, and A.M. Scott Radiation dose to PET technologists and strategies to lower occupational exposure J. Nucl. Med. Technol. 33 2005 44 47
26. A. Michna, Z. Adamczyk, M. Ocwieja, and E. Bielanska Kinetics of silver nanoparticle deposition onto poly(ethylene imine) modified mica determined by AFM and SEM measurements Colloids Surf. A 377 2011 261 268
27. D.T.R. Stewart, M.D. Celiz, G. Vicente, L.A. Colin, and D.S. Aga Potential use of capillary zone electrophoresis in size characterization of quantum dots for environmental studies Trends Anal. Chem. 30 2011 113 122
28. V.Y. Rudyak, A.A. Belkin, and V.V. Egorov On the effective viscosity of nanosuspensions Tech. Phys. 54 2009 1102 1109
29. G. Buckton, A. Choularton, A.E. Beezer, and S.M. Chatham The effect of the comminution technique on the surface energy of a powder Int. J. Pharm. 47 1988 121 128
30. A. Kwade, L. Blecher, and J. Schwedes Motion and stress intensity of grinding beads in a stirred media mill. Part 2: stress intensity and its effect on comminution Powder Technol. 86 1996 69 76
31. F. Tajarobi, A. Larsson, H. Matic, and S. Abrahmsen-Alami The influence of crystallization inhibition of HPMC and HPMCAS on model substance dissolution and release in swellable matrix tablets Eur. J. Pharm. Biopharm. 78 2011 125 133
32. H. Konno, T. Handa, D.E. Alonzo, and L.S. Taylor Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine Eur. J. Pharm. Biopharm. 70 2008 493 499
33. P. Vishweshwar, J.A. McMahon, J.A. Bis, and M.J. Zaworotko Pharmaceutical co-crystals J. Pharm. Sci. 95 2006 499 516
34. A.V. Yadav, A.S. Shete, A.P. Dabke, P.V. Kulkarni, and S.S. Sakhare Co-crystals: a novel approach to modify physicochemical properties of active pharmaceutical ingredients Indian J. Pharm. Sci. 71 2009 359 370
35. G.R. Desiraju Crystal engineering: solid state supramolecular synthesis Curr. Opin. Solid State Mater. Sci. 2 1997 451 454
36. G.R. Desiraju Crystal engineering: a brief overview J. Chem. Sci. 122 2010 667 675
37. G.R. Desiraju Crystal engineering: a holistic view Angew. Chem. Int. Ed Engl. 46 2007 8342 8356
38. F. Meyer-Wegner, H.W. Lerner, and M. Bolte C-H.pi interactions in cocrystals of bis(trimethylsilyl)acetylene and diphenylacetylene with benzene Acta Crystallogr. C 66 2010 o182 o184
39. S.G. Ortiz, T. Ma, N.J. Epstein, R.L. Smith, and S.B. Goodman Validation and quantification of an in vitro model of continuous infusion of submicron-sized particles J. Biomed. Mater. Res. B Appl. Biomater. 84 2008 328 333
40. T. Ma, Z. Huang, P.G. Ren, R. McCally, D. Lindsey, R.L. Smith, and S.B. Goodman An in vivo murine model of continuous intramedullary infusion of polyethylene particles Biomaterials 29 2008 3738 3742
41. J.A. MacKay, D.F. Deen, and J. Szoka Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating Brain Res. 1035 2005 139 153
42. J.M. Megaw, and S. Lerman Application of miniosmotic pumps for liposomal drug delivery to the ocular lens Invest. Ophtalmol. Vis. Sci. 28 1987 1429 1433
43. M.H. Bourguignon, E.K. Pauwels, and C. Loc'h, and B. Maziere Iodine-123 labelled radiopharmaceuticals and single-photon emission tomography: a natural liaison Eur. J. Nucl. Med. 24 1997 331 344
44. 177Lu: in vivo comparison of macrocyclic and acyclic ligands Nucl. Med. Biol. 34 2007 173 183
45. 125I uptake-blocking activity in breast cancer J. Clin. Endocrinol. Metab. 85 2000 1245 1250
46. K. Hirano, and H. Yamada Studies on the absorption of practically water-insoluble drugs following injection VI: subcutaneous absorption from aqueous suspensions in rats J. Pharm. Sci. 71 1982 500 505
47. L. Harivardhan Reddy, R.K. Sharma, K. Chuttani, A.K. Mishra, and R.S.R. Murthy Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice J. Control. Release 105 2005 185 198
48. A.E. Hawley, S.S. Davis, and L. Illum Targeting of colloids to lymph nodes: influence of lymphatic physiology and colloidal characteristics Adv. Drug Deliv. Rev. 17 1995 129 148
49. D. McLennan Subcutaneous drug delivery and the role of the lymphatics Drug Discov. Today 2 2005 89 96
50. C. Oussoren, and G. Storm Liposomes to target the lymphatics by subcutaneous administration Adv. Drug Deliv. Rev. 50 2001 143 156
51. S.S. Ober, H.C. Vincent, D.E. Simon, and K.J. Frederick A rheological study of procaine penicillin G depot preparations J. Am. Pharm. Assoc. Am. Pharm. Assoc. (Baltim.) 47 1958 667 676
52. Y. Sato, A. Yokoyama, K. Shibata, Y. Akimoto, S. Ogino, Y. Nodasaka, T. Kohgo, K. Tamura, T. Akasaka, M. Uo, K. Motomiya, B. Jeyadevan, M. Ishiguro, R. Hatakeyama, F. Watari, and K. Tohji Influence of length on cytotoxicity of multi-walled carbon nanotubes against human acute monocytic leukemia cell line THP-1 in vitro and subcutaneous tissue of rats in vivo Mol. Biosyst. 1 2005 176 182
53. J.M. Morais, F. Papadimitrakopoulos, and D.J. Burgess Biomaterials/tissue interactions: possible solutions to overcome foreign body response AAPS J. 12 2010 188 196